Japan Daily Briefing

The US-Japan yen intervention dynamic has traders glued to USD/JPY, with BoJ's Finance Minister Katayama watching exchange rates closely. The prior session's Nikkei sell-off (-2%+) was directly attributed to yen strength hitting Toyota, Sony, and the broader export complex. Today's recovery suggests the market found a near-term equilibrium — BoJ's silence above 155 is being read as tolerance. Automakers (HMC +1.99%) led the recovery; if USD/JPY breaks below 150, that calculus reverses fast.

The prior session's Nikkei drop of over 2% — triggered by yen appreciation against the dollar — created the setup for today's rebound. With USD/JPY stabilizing, auto and industrial exporters recovered sharply: Industrials +2.47%, Autos +1.94%. The TOPIX-vs-Nikkei divergence bears watching: when value names (trading houses, banks) outperform tech, it signals rotation into the Buffett-Japan theme. Today, banks were flat (-0.11%) while growth names (SoftBank +7.2%) led — a growth-not-value day.

Takeda (TAK) held its Q1 2026 earnings call — Pharma was the sole sector in the red today at -1.13%. Takeda's pipeline review and guidance update will be closely parsed by Japan pharma investors. The broader Japan pharma trade has been defensive amid yen uncertainty; any guidance cut from Takeda amplifies the rotation away from pharma into industrials and semicap. This sector divergence — pharma lagging while semis lead — is a pattern worth tracking as BoJ normalization continues.